Showing results (311-320 of 394) with videos related to

Sort By:
Pageof 40
Journal of Nanoscience and Nanotechnology|December 5, 2008
Evolution of photoluminescence mechanisms of Si(+)-implanted SiO2 films with thermal annealingL Ding, T P Chen, Y Liu, et al.
Journal of Virology|September 1, 1989
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120N C Sun, D D Ho, C R Sun, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancerKarthikeyani Chellappa, Lucy Jankova, Jake M Schnabl, et al.
Hematology (Amsterdam, Netherlands)|September 7, 2020
IgG4 plasma cell myeloma without clinical evidence of IgG4-related disease: a report of two casesDeonne Thaddeus V Gauiran, Krista M Marcon, Mari L DeMarco, et al.
Hormone Research in Paediatrics|August 28, 2022
Vitamin D Toxicity from an Unusual and Unexpected Source: A Report of 2 CasesCarolina Silva, Angela W S Fung, Vanessa Masson, et al.
BMC Nephrology|February 6, 2020
Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policyCarlos K H Wong, Julie Chen, Samuel K S Fung, et al.
Bioorganic & Medicinal Chemistry|November 23, 2013
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1)Sai-Parng S Fung, Haiyan Wang, Petr Tomek, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I studyZ Kassam, H Mackay, C A Buckley, et al.
Eye (London, England)|May 30, 2015
Hybrid procedure for orbital venous malformation in the endovascular operation roomA C O Cheng, E Y M Li, T C Y Chan, et al.
Cancer Medicine|May 8, 2020
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumabAndrea S Fung, Vincent C Tam, Daniel E Meyers, et al.
Pageof 40